|
|
Post by mnholdem on Feb 23, 2019 9:42:08 GMT -5
Link: diatribe.org/2019-jdrf-mission-summit-highlights-hope-cure-and-new-t1d-treatments2019 JDRF Mission Summit Highlights Hope for a Cure and New T1D Treatments2/22/19 - CONFERENCE PEARLS Excerpt: "In addition, Dr. Sherr also shared excitement for using Symlin, an injectable non-insulin treatment approved for both type 1 and type 2 diabetes, and Afrezza, an inhalable insulin. Dr. Kowalski is a believer in a Symlin-insulin combination for automated insulin delivery (AID) systems – Symlin reduces post-meal blood sugar peaks, which makes it well suited for automated insulin delivery. A recent study showed that the combination of insulin and Symlin increased time-in-range by nearly three hours per day (!) compared to insulin-alone AID systems. Afrezza is also being tested in combination with automated insulin delivery, helping to blunt the post-meal increase in blood sugar." |
|
|
|
Post by mannmade on Feb 23, 2019 12:51:47 GMT -5
This is a big deal! As many may know Dr. Kowalski is jdrf’s chief Scientist and a user of afrezza. Although he has never been very public about it. Perhaps this is about to change.
|
|
|
|
Post by peppy on Feb 24, 2019 9:03:39 GMT -5
This is a big deal! As many may know Dr. Kowalski is jdrf’s chief Scientist and a user of afrezza. Although he has never been very public about it. Perhaps this is about to change. , where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our strength lies in our exclusive focus and singular influence on the worldwide effort to end T1D. Vision: A world without type 1 diabetes Mission: Improving lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications ====================================================================================== www.accessdata.fda.gov/drugsatfda_docs/label/2014/021332s007_S016.pdfSYMLIN is an amylin analog indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy. Symlin has a black box warning. 12.1 Mechanism of Action Pramlintide is an analog of human amylin. Amylin is colocated with insulin in secretory granules and cosecreted with insulin by pancreatic beta cells in response to food intake. Amylin and insulin show similar fasting and postprandial patterns in healthy individuals (Figure 1). In patients with type 1 and type 2 diabetes, there is reduced secretion from pancreatic beta cells of both insulin and amylin in response to food. Amylin affects the rate of postprandial glucose appearance through a variety of mechanisms, as determined by nonclinical studies. Amylin slows gastric emptying (i.e., the rate at which food is released from the stomach to the small intestine) without altering the overall absorption of nutrients. In addition, amylin suppresses glucagon secretion (not normalized by insulin alone), which leads to suppression of endogenous glucose output from the liver. Amylin also regulates food intake due to centrally-mediated modulation of appetite. In human studies, pramlintide, acting as an amylin analog, slows gastric emptying, reduces the postprandial rise in plasma glucagon, and modulates satiety leading to decreased caloric intake. |
|
|
|
Post by agedhippie on Feb 24, 2019 10:30:01 GMT -5
This is a big deal! As many may know Dr. Kowalski is jdrf’s chief Scientist and a user of afrezza. Although he has never been very public about it. Perhaps this is about to change. , where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our strength lies in our exclusive focus and singular influence on the worldwide effort to end T1D. Vision: A world without type 1 diabetes Mission: Improving lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications ====================================================================================== www.accessdata.fda.gov/drugsatfda_docs/label/2014/021332s007_S016.pdfSYMLIN is an amylin analog indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy. Symlin has a black box warning. 12.1 Mechanism of Action Pramlintide is an analog of human amylin. Amylin is colocated with insulin in secretory granules and cosecreted with insulin by pancreatic beta cells in response to food intake. Amylin and insulin show similar fasting and postprandial patterns in healthy individuals (Figure 1). ... Amylin is made by beta cells so T1s lose that along with insulin. Symlin was invented to mimic it, but it has problems so most just live with the missing amylin and accept the impact on control. There is not a lot of interest in looking at amylin for diabetics. Next up c-peptide which they used to think were a waste byproduct produced in insulin production and are now beginning to think may well help repair cardio damage. Diabetes is a whole eco-system of it's own, insulin is just the most visible part. |
|
